Immunocore (IMCR) Q2 FY26 earnings call

Immunocore delivered robust Q2 FY26 results, driven by continued strong commercial momentum for KIMMTRAK, supported by landmark 5-year overall survival data. The company is advancing a diversified pipeline, with key Phase III trials nearing data readouts and early-stage programs progressing in autoimmune and infectious diseases. While facing near-term rebate payments and inventory adjustments, the company's financial position remains strong, providing flexibility for continued investment and growth.